The Central Drugs Standard Control Organization, India’s drug regulatory body, said it will create a national digital database of pharmaceutical manufacturers and their medicines to help address drug shortages and quality issues.

The regulatory agency told the Economic Times it is in the process of finalizing the software to be used for the database and will amend its rules and regulations to make it mandatory for manufacturers to regularly put details of their facilities and products into the database.

India does not have a comprehensive, real-time information database on drugmakers in the country. The regulatory agency currently relies on information gathered by state authorities, who often don’t know what drugs are produced in other states.

Whitepaper Download Reducing the Complexity and Costs of Channel Planning and Logistics How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business. Download for Free

“Now, there is going to be a completely transparent system with proper data management,” a senior government official, who was not identified, told the newspaper.

The software system is expected to be ready and will be discussed at a meeting of the agency and state drug regulators next week.

Indian drugmakers have been a particular target of the FDA and European Medicines Agency in the past few years. Those agencies have cited—and in some cases banned—a number of manufacturers for violations that span the range from vermin in factories to sloppy or falsified record keeping.